Although the castration treatment with androgen receptor (AR) antagonist is an effective therapeutic approach for prostate cancer, many patients become marked resistance to treatment and further progressed to castration-resistant disease (CRPC) [15]. The gene discussed is AR; the disease is prostate carcinoma.